Advanced in Peripheral T-Cell Lymphoma

Shu Cheng

No. 197, Ruijin 2nd Rd, 
Shanghai, CN 
Advanced in Peripheral T-Cell Lymphoma
No. 197, Ruijin 2nd Rd, 
Shanghai, CN 
OverviewLocationsClinical Research

Overview

Shu Cheng practices in Shanghai, China. Cheng is rated as an Advanced expert by MediFind in the treatment of Peripheral T-Cell Lymphoma. Their top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, and Splenectomy.

Their clinical research consists of co-authoring 95 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 8 articles in the study of Peripheral T-Cell Lymphoma.

Locations

No. 197, Ruijin 2nd Rd, Shanghai, 200025, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Chidamide Combined With CHOP(Cyclophosphamide, Doxorubicin, Vincristine, Prednisone ) in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma
A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Chidamide Combined With CHOP(Cyclophosphamide, Doxorubicin, Vincristine, Prednisone ) in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma
Enrollment Status: Unknown
Publish Date: April 20, 2022
Intervention Type: Drug
Study Drugs: Chidamide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Study Phase: Phase 2
A Phase 1, Open-Label Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Adult Subjects With Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
A Phase 1, Open-Label Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Adult Subjects With Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Unknown
Publish Date: July 12, 2019
Intervention Type: Biological
Study Drug: CD19 CAR-T Cells
Study Phase: Phase 1
View 1 Less Clinical Trial

95 Total Publications

An online detection method for municipal sludge moisture content based on ultrasonic transmission technology.
An online detection method for municipal sludge moisture content based on ultrasonic transmission technology.
Journal: Journal of environmental management
Published: May 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Cheng's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile